Physician profile
Mitchell B Weisberg
NPI 1336120906
$868.80
in general payments reported to CMS, 2019-2025
23 companies · $59.32 in 2025
The $59.32 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $211 · 2021: $34.46 · 2023: $47.78 · 2025: $59.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $94.30 · Education: $12.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $94.30 |
| Education | $12.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $133.41 | 2019-2025 | Iclusig, Ninlaro |
| Otsuka America Pharmaceutical, INC. | $122.23 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $96.83 | 2019-2020 | |
| Foundation Medicine, INC. | $78.59 | 2019-2020 | |
| Pfizer INC. | $69.28 | 2019-2025 | |
| Amgen INC. | $47.16 | 2019-2023 | |
| Astellas Pharma US INC | $36.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $30.86 | 2019 | |
| Seagen INC. | $26.68 | 2019-2020 | |
| Janssen Biotech, INC. | $24.20 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.46 | 2020 | |
| Taiho Oncology, INC. | $19.79 | 2025 | |
| Emd Serono, INC. | $18.42 | 2019 | |
| Array Biopharma INC | $17.29 | 2019 | |
| Lilly USA, LLC | $16.92 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.77 | 2019 | |
| Stemline Therapeutics INC. | $15.91 | 2023 | Orserdu |
| Abbvie INC. | $13.76 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.06 | 2019 | |
| Rigel Pharmaceuticals, INC. | $12.88 | 2019 | |
| Genentech USA, INC. | $12.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.06 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Weisberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.